COMPANY
Alleviant Medical, Inc.
Funding and NIH signals
- NIH award NIH awarded $996K (SBIR Phase II 5R44HL142440-06, continuation, notice May 13, 2026). NIH RePORTER 5R44HL142440-06 (May 13, 2026)
Evidence (1 event)
- May 13, 2026 · NIH RePORTER 5R44HL142440-06
Organization: ALLEVIANT MEDICAL, INC.; City/State: Austin, TX; Project number: 5R44HL142440-06; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-13; FY total cost (award amount): 996173; Administering IC: National Heart Lung and Blood Institute; Project title: Transcatheter Device for Congestive Heart Failure Treatment Through Left Atrial Decompression; Organization type: Domestic For-Profits
- May 13, 2026 · NIH RePORTER 5R44HL142440-06
Timeline
- Grant Government grant — SBIR: $996,173 (annual award, as published), announced May 13, 2026. Agency: NIH/NHLBI. Source: government award database. source ↗
- Trial start Not phased (device or behavioral study): Alleviant ALLAY-HFrEF Study source ↗
- Grant Government grant — SBIR: $992,964 (annual award, as published), announced Feb 19, 2025. Agency: NIH/NHLBI. Source: government award database. source ↗
- Trial start Not phased (device or behavioral study): Alleviant ALLAY-HF Study source ↗
- Trial start Phase 1: ALLEVIATE-HF-HD Study source ↗
- Trial start Phase 1: ALLEVIATE-HFrEF Study source ↗
- Trial start Not phased (device or behavioral study): Alleviate-HF-2 Study source ↗
- Trial start Phase 1: Alleviate-HF-1 Study source ↗
Upcoming milestones
- Dec 1, 2027 (ESTIMATED) · Not phased · Alleviant ALLAY-HF Study · NCT05685303
- 2028-12 (ESTIMATED) · Not phased · Alleviant ALLAY-HFrEF Study · NCT06812533
Funding
- Government grant — SBIR: $996,173 (annual award, as published), announced May 13, 2026. Agency: NIH/NHLBI. Source: government award database. source ↗
- Government grant — SBIR: $992,964 (annual award, as published), announced Feb 19, 2025. Agency: NIH/NHLBI. Source: government award database. source ↗
Clinical trials (lead sponsor) 6
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06812533 | Alleviant ALLAY-HFrEF Study | Not phased (device or behavioral study) | Recruiting | Mar 10, 2025 | 2028-12 (estimated) |
| NCT05685303 | Alleviant ALLAY-HF Study | Not phased (device or behavioral study) | Recruiting | Jan 10, 2023 | Dec 1, 2027 (estimated) |
| NCT04838353 | Alleviate-HF-2 Study | Not phased (device or behavioral study) | Completed | Apr 3, 2021 | Sep 1, 2023 (actual) |
| NCT05133089 | ALLEVIATE-HFrEF Study | Phase 1 | Completed | Aug 10, 2021 | Mar 10, 2022 (actual) |
| NCT05501652 | ALLEVIATE-HF-HD Study | Phase 1 | Completed | Jun 30, 2022 | Aug 22, 2022 (actual) |
| NCT04583527 | Alleviate-HF-1 Study | Phase 1 | Completed | Aug 11, 2020 | Aug 16, 2021 (actual) |
NIH awards 5
- NIH award 1SB1HL174252-01 FY2024: $499,103 awarded for that fiscal year; activity SB1 (SBIR); PI PATE, THOMAS DIFFLEY; recipient as written: ALLEVIANT MEDICAL, INC., Austin, TX. Advancing Commercial Readiness of a No source ↗
- NIH award 2R44HL142440-04 FY2024: $997,944 awarded for that fiscal year; activity R44 (SBIR); PI PATE, THOMAS DIFFLEY; recipient as written: ALLEVIANT MEDICAL, INC., Austin, TX. Transcatheter Device for Congestive He source ↗
- NIH award 5R44HL142440-03 FY2023: $1,017,154 awarded for that fiscal year; activity R44 (SBIR); PI PATE, THOMAS DIFFLEY; recipient as written: ALLEVIANT MEDICAL, INC., Austin, TX. Transcatheter Device for Congestive source ↗
- NIH award 2R44HL142440-02A1 FY2022: $898,558 awarded for that fiscal year; activity R44 (SBIR); PI PATE, THOMAS DIFFLEY; recipient as written: ALLEVIANT MEDICAL, INC., Austin, TX. Transcatheter Device for Congestive source ↗
- NIH award 1R43HL142440-01 FY2018: $313,587 awarded for that fiscal year; activity R43 (SBIR); PI PATE, THOMAS DIFFLEY; recipient as written: ALLEVIANT MEDICAL, INC., Austin, TX. Transcatheter Device for Congestive He source ↗